These results implied that reduced tumor uptake of 89Zr-DFO-pertuzumab in 17-DMAG-treated groups was caused by not an antiangiogenic effect but HER2 downregulation of 17-DMAG treatment in JIMT-1 tumors. The gene discussed is ERBB2; the disease is neoplasm.